Published in
American Society of Hematology, Blood Advances, 10(2), p. 1157-1169, 2018
DOI: 10.1182/bloodadvances.2017015214
Links
Tools
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase
Journal article published in 2018 by
Sarah E. Fordham,
Helen J. Blair,
Claire J. Elstob,
Ruth Plummer,
Yvette Drew,
Nicola J. Curtin,
Olaf Heidenreich,
Deepali Pal,
David Jamieson 
,
Catherine Park,
John Pollard,
Scott Fields,
Paul Milne,
Graham H. Jackson,
Helen J. Marr
and other authors.
,
Catherine Park,
John Pollard,
Scott Fields,
Paul Milne,
Graham H. Jackson,
Helen J. Marr
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key PointsLoss of ATR signaling is cytotoxic to AML cells in combination with gemcitabine and hydroxyurea via the induction of replication stress. A small molecule inhibitor of ATR in combination with gemcitabine completely eradicates AML in an orthotopic xenograft mouse model.